SCHEMBL22909284

SCHEMBL22909284

COc1ccc(CN(c2ccc(OC)c(F)c2)S(=O)(=O)c2c(F)c(F)c(F)c(F)c2CO)cc1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 3/20 0.47
CNR2 P34972 4/20 0.40
CNR1 P21554 3/20 0.40
PGR P06401 2/20 0.40
NR3C1 P04150 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KEAP1 Q14145 4/20 0.39
NFE2L2 Q16236 4/20 0.39
MCL1 Q07820 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29671272 1.00 TAS2R14 (0.47) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL29671217 0.91 TAS2R14 (0.46) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL22909520 0.91 TAS2R14 (0.46) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL29671234 0.87 TAS2R14 (0.47) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL22909525 0.87 TAS2R14 (0.47) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL28762106 0.85 TAS2R14 (0.53) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL28762040 0.85 PGR (0.45) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL29671209 0.85 PGR (0.45) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL22909285 0.85 TAS2R14 (0.46) TAS2R14CNR2CNR1PGRNR3C1
SCHEMBL29671198 0.85 TAS2R14 (0.46) TAS2R14CNR2CNR1PGRNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114502533-A Benzenesulfonamide derivatives and use thereof 2692372安大略公司 2022-05-13 CN disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed